Myelodysplasia and myeloproliferative disorders in children

Area of Science:

• Pediatric Hematology
• Oncology
• Genetics

Background:

• Myelodysplastic syndromes (MDSs) are uncommon in children, representing less than 10% of pediatric hematopoietic malignancies.
• Approximately one-third of pediatric MDS cases are associated with a predisposing genetic condition.
• Classifying pediatric MDS is challenging due to overlapping features with chronic myeloproliferative diseases and differences from adult criteria.

Purpose of the Study:

• To summarize the key aspects of pediatric myelodysplastic syndromes.
• To highlight the unique classifications and challenges in diagnosing MDS in children.
• To identify prognostic indicators and differential diagnoses in pediatric MDS.

Main Methods:

• Review of existing literature on pediatric myelodysplastic syndromes.
• Analysis of classification systems for pediatric MDS.
• Identification of common cytogenetic abnormalities and prognostic factors.

Main Results:

• Two primary groups of pediatric MDS exist: juvenile myelomonocytic leukemia and adult-type MDS.
• Monosomy 7 is the most frequent cytogenetic abnormality in pediatric MDS.
• Younger age at diagnosis (<1 year), low platelet count, elevated hemoglobin F, and complex cytogenetics are associated with better survival and unfavorable prognosis, respectively.

Conclusions:

• Pediatric MDS requires distinct diagnostic and classification approaches compared to adults.
• Genetic factors and specific cytogenetic abnormalities play a significant role in pediatric MDS.
• Accurate diagnosis and prognostic assessment are crucial for managing pediatric MDS, considering both neoplastic and non-neoplastic causes.